Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milvexian PK/Safety in ESRD on Hemodialysis
NCT02902679Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of milvexian in thrombosis, sponsored by Bristol Myers Squibb. Primary endpoints: Number of subjects with Adverse events (AEs), Change from baseline in Physical examination parameters and 3 more. Started Nov 2016; status: completed.
02
Drugs
milvexian
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT02902679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902679.